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Abstract
The pregnane X receptor is a ligand-activated transcription factor that is abundantly expressed in
hepatocytes. Numerous drugs are pregnane X receptor ligands. To bind to their receptor they must cross
the sinusoidal membrane. Organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 and
OATP1B3) are polyspecific transporters expressed at the sinusoidal membrane of human hepatocytes.
They mediate transport of a variety of drugs including the pregnane X receptor ligands rifampicin and
dexamethasone. To test whether additional pregnane X receptor ligands interact with OATP1B1- and
1B3-mediated transport, we developed Chinese Hamster Ovary (CHO) cell lines stably expressing
OATP1B1 or 1B3 at high levels. OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide uptake
was inhibited by several pregnane X receptor ligands in a concentration dependent way. IC(50) values
for rifampicin, paclitaxel, mifepristone, and troglitazone were within their respective pharmacological
free plasma concentrations. Kinetic analysis revealed that clotrimazole inhibits OATP1B1-mediated
estradiol-17beta-glucuronide transport with a K(i) of 7.7+/-0.3 microM in a competitive way. However,
uptake of OATP1B3-mediated estradiol-17beta-glucuronide was stimulated and this stimulation was due
to an increased apparent affinity. Transport of estrone-3-sulfate was hardly affected while all other
substrates tested were inhibited. Additional azoles like fluconazole, ketoconazole and miconazole did
not stimulate OATP1B3-mediated estradiol-17beta-glucuronide transport. In summary, these results
demonstrate that pregnane X receptor ligands, by inhibiting or stimulating OATP-mediated uptake, can
lead to drug-drug interactions at the transporter level.
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Abstract 
The pregnane X receptor is a ligand-activated transcription factor that is abundantly 
expressed in hepatocytes. Numerous drugs are pregnane X receptor ligands. To bind to 
their receptor they must cross the sinusoidal membrane. Organic anion transporting 
polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) are polyspecific transporters 
expressed at the sinusoidal membrane of human hepatocytes. They mediate transport 
of a variety of drugs including the pregnane X receptor ligands rifampicin and 
dexamethasone. To test whether additional pregnane X receptor ligands interact with 
OATP1B1- and 1B3-mediated transport, we developed Chinese Hamster Ovary (CHO) 
cell lines stably expressing OATP1B1 or 1B3 at high levels. OATP1B1- and 1B3-
mediated estradiol-17β-glucuronide uptake was inhibited by several pregnane X 
receptor ligands in a concentration dependent way. IC50 values for rifampicin, paclitaxel, 
mifepristone, and troglitazone were within their respective pharmacological free plasma 
concentrations. Kinetic analysis revealed that clotrimazole inhibits OATP1B1-mediated 
estradiol-17β-glucuronide transport with a Ki of 7.7 ± 0.3 μM in a competitive way. 
However, uptake of OATP1B3-mediated estradiol-17β-glucuronide was stimulated and 
this stimulation was due to an increased apparent affinity. Transport of estrone-3-sulfate 
was hardly affected while all other substrates tested were inhibited. Additional azoles 
like fluconazole, ketoconazole and miconazole did not stimulate OATP1B3-mediated 
estradiol-17β-glucuronide transport. In summary, these results demonstrate that 
pregnane X receptor ligands, by inhibiting or stimulating OATP-mediated uptake, can 
lead to drug-drug interactions at the transporter level.   
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1. Introduction 
Nuclear receptors are ligand-activated transcription factors that play an important role in 
xenobiotic disposition and human diseases like diabetes, obesity and cancer (Giguere, 
1999; Wang and LeCluyse, 2003). Numerous clinically prescribed drugs including 
dexamethasone and rifampicin are ligands of the human pregnane X receptor, which is 
highly expressed in hepatocytes. By binding to their receptors, these drugs regulate the 
expression of many drug-metabolizing enzymes (Xie et al., 2004) and transporters (Guo 
et al., 2002). Therefore they can affect the metabolism of the majority of drugs. With the 
exception of rifampicin (Vavricka et al., 2002), paclitaxel (Smith et al., 2005) and 
lithocholate (Yamaguchi et al., 2006), it is largely unknown how pregnane X receptor  
ligands enter hepatocytes to bind to their receptor, but in general it is assumed to be by 
simple diffusion. 
Organic anion transporting polypeptides (rodents: Oatps; human: OATPs) belong to a 
growing superfamily of transport proteins that mediate uptake of structurally diverse 
amphiphilic organic solutes (Hagenbuch and Meier, 2004). Among the 11 human 
OATPs, OATP1B1 and OATP1B3 are liver specific transporters that are multispecific 
and mediate the uptake of numerous drugs into hepatocytes (Hagenbuch and Meier, 
2003). Previous work has shown that the glucocorticoid dexamethasone and the 
antibiotic rifampicin directly interact with OATPs. We demonstrated that dexamethasone 
inhibits OATP1A2-mediated dehydroepiandrosterone sulfate transport (Kullak-Ublick et 
al., 1998) in addition to being a substrate of rat Oatp1a1 (Bossuyt et al., 1996). 
Furthermore, we reported that rifampicin inhibits transport mediated by Oatp1a1 and 
Oatp1a4 (Fattinger et al., 2000). A more recent study showed that rifampicin not only 
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inhibits human OATP1B1 and OATP1B3 but is directly transported by both OATPs 
(Vavricka et al., 2002).  
Because drug-drug interactions can occur due to direct inhibition of uptake into liver in 
which OATP1B1 and OATP1B3 are expressed, we hypothesized that additional, readily 
available pregnane X receptor  ligands including carbamazepine, clotrimazole, estradiol, 
lithocholate, metyrapone, mevinolin, mifepristone, paclitaxel, phenytoin, and troglitazone 
(Goodwin et al., 1999; Honkakoski et al., 2003) would interact with OATP1B1- and 
OATP1B3-mediated transport. To test this hypothesis, we developed Chinese Hamster 
Ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3 and determined 
substrate uptake into these cells in the presence as well as absence of pregnane X 
receptor ligands.  
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2. Materials and Methods 
2.1 Materials 
Radiolabeled [3H]estradiol-17β-glucuronide (39.8 Ci/mmol) and [3H]estrone-3-sulfate 
(57.3 Ci/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA), and 
[3H]clotrimazole ( 7.5 Ci/mmol) from Moravek Biochemicals Inc. (Brea, CA). The cell-
impermeant Fluo-3, pentapotassium salt was obtained from Invitrogen (Carlsbad, CA). 
Cell culture reagents were from Invitrogen (Carlsbad, CA) and fetal bovine serum from 
Hyclone (Logan, UT). All pregnane X receptor ligands were purchased from Sigma (St. 
Louis, MO) and stock solutions were prepared in ethanol or DMSO.  
 
2.2 Cell culture, generation of stable cell lines and uptake experiments 
Chinese Hamster Ovary (CHO) cells were grown at 37 °C in a humidified 5% CO2 
atmosphere in Dulbecco’s Modified Eagle Medium, containing 1 g/l D-glucose, 2 mM L-
glutamine, 25 mM Hepes buffer and 110 mg/l sodium pyruvate, supplemented with 10% 
FBS (Hyclone, Logan, UT), 50 µg/ml L-proline, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Open reading frames of OATP1B1*1b (Tirona et al., 2001) and OATP1B3 
haplotype 1 (Smith et al., 2007) were PCR amplified using Pfu DNA Polymerase 
(Stratagene, La Jolla, CA) and cloned into the vector pIRESneo2 (Clontech, Mountain 
View, CA).  After sequencing the plasmids, CHO cells were stably transfected by 
electroporation. Initially, the cell culture medium was supplemented with 1 mg/ml G-418. 
After single clones were isolated using cloning cylinders followed by limiting dilution, G-
418 concentration was lowered to 500 μg/ml. Clones were characterized for transport 
and immunoflourescence and one clone for each OATP was used for further work. 
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For uptake experiments CHO-wild-type and OATP-expressing cells were plated at 
40,000 cells per well on 24-well plates and 48-h later medium was replaced with 
medium containing 5mM sodium-butyrate to induce nonspecific gene expression 
(Palermo et al., 1991). After another 24 h in culture, the cells were used for uptake 
experiments. Cells were washed three times with pre-warmed uptake buffer (116.4 mM 
NaCl, 5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose and 20 mM 
Hepes, pH adjusted to 7.4 with Trizma base). Uptake was started by adding 200 μl of 
uptake buffer containing 0.3 to 0.6 μCi/ml of the radiolabeled substrate in the presence 
or absence of inhibitors. After 20 s, at previously determined initial linear rate conditions, 
uptake was stopped by removing the uptake solution and washing the cells four times 
with ice-cold uptake buffer. The cells were then solubilized with 500 μl of 1% Triton X-
100. Three hundred micro liters were used for liquid scintillation counting, and protein 
concentration was determined using the BCA assay with bovine serum albumin as a 
standard. Uptake of the anionic substrate Fluo-3 (Cui et al., 2001a) was determined 
essentially the same, except that the uptake was stopped after 10 min (the initial linear 
portion of uptake extended well over 10 min) and the cells were solubilized in the 
presence of 1 mM CaCl2. Fluorescence was measured in a Bio-Tek Synergy HT 
microplate reader (Winooski, VT) at an excitation wavelength of 485 nm and an 
emission wavelength of 528 nm. Uptake rates were always calculated based on net 
uptake after subtracting the values obtained with wild-type CHO cells. 
 
2.3 Immunofluorescence 
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For immunofluorescence, 30,000 cells were plated on culture slides (BD Biosciences, 
Bedford, MA) and induced with 5 mM sodium-butyrate 24 h before fixation. Cells were 
then fixed in 4% paraformaldehyde, 1% TX-100 in PBS for 1 h at room temperature. 
After washing, the cells were incubated with 5% BSA in PBS at room temperature for 1 
h. After another wash with PBS, cells were incubated with anti-OATP1B1 (1:500) or 
anti–OATP1B3 (1:500) antibody in 1% BSA in PBS. Slides were then washed with PBS 
and incubated with Alexa Fluor 594 goat anti-rabbit IgG(H+L) (Invitrogen) for 1 h at room 
temperature. After a final wash with PBS, slides were mounted with VECTASHIELD 
Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA) and used for 
confocal image analysis.  
Fluorescent digital images were obtained using a Zeiss LSM510 confocal microscope 
equipped with a HeNe laser (1 mW) for the excitation (543 nm, 100% laser power) and 
detection (long pass 560 nm filter; LP560) of the Alexa Fluor 543/594.  Images were 
acquired in Multitrack channel mode (sequential excitation/emmision) with LSM510 (v 
3.2) software and a Plan-Apochromat 63X/1.4 Oil DIC objective with a zoom factor of 1 
(field size of 0.146 mm x 0.146 mm) and frame size of 1024X1024 pixels. Detector gain 
was set initially to cover the full range of all the samples and background corrected by 
setting the amplifier gain, and all images were then collected under the same 
photomultiplier detector conditions and pinhole diameter. Control slides consisted of 
untransfected wild-type CHO cells.  
 
2.4 Data analysis 
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IC50 and kinetic parameters were calculated using non-linear regression analysis and 
SigmaPlot (Version 9.01; Systat Software, Inc., Point Richmond, CA). To analyze 
whether the groups were different from the control, ANOVA was performed followed by 
the Bonferroni test (GraphPad InStat Version 3, GraphPad Software, Inc., San Diego, 
CA). The P value for statistical significance was set to < 0.05. 
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3. Results 
3.1 Characterization of OATP1B1 and OATP1B3 cell lines  
We constructed CHO cell lines that stably express the most frequent variants of 
OATP1B1 (OATP1B1*1b or N130D) (Tirona et al., 2001) and OATP1B3 (haplotype 1 or 
S112A and M233I) (Smith et al., 2007). To demonstrate expression of OATP1B1 and 
1B3 in the generated CHO cell lines, we used confocal microscopy. The results shown 
in Fig. 1 (A and B) demonstrate that the respective cell lines expressed OATP1B1 or 
1B3 at the plasma membrane. To functionally characterize these OATP1B1- and 1B3-
expressing CHO cells and measure some basic kinetic constants we first determined the 
initial linear portion of uptake. Uptakes of estradiol-17β-glucuronide and estrone-3-
sulfate were linear for at least 20 s while uptake of Fluo-3 was linear over more than 10 
min. Therefore, all experiments were performed at 20 s for estradiol-17β-glucuronide 
and estrone-3-sulfate and at 10 min for Fluo-3. Fig. 1 (C and D) shows an example of 
saturation kinetics for estradiol-17β-glucuronide. Uptake was saturable with increasing 
concentrations of substrate for both OATP1B1- and 1B3-expressing cells. OATP1B1 
exhibited an approximately 3-fold higher affinity than OATP1B3 with similar maximal 
transport rates (Fig. 1C and 1D; Table 1). Comparison of estrone-3-sulfate uptake 
mediated by both OATPs revealed that OATP1B1 represents a high-affinity low-capacity 
transporter, whereas OATP1B3 has low-affinity but high-capacity for estrone-3-sulfate 
uptake (Table 1). Fluo-3 was transported by both carriers with a similar affinity, but 
OATP1B3-mediated transport had an almost 10-fold higher capacity (Table 1).  
 
3.2 Effect of pregnane X receptor ligands on estradiol-17β-glucuronide transport  
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To test whether pregnane X receptor  ligands besides the known rifampicin interact with 
OATP1B1- and 1B3-mediated transport, we quantified uptake of 1 μM estradiol-17β-
glucuronide in the absence and presence of 10 and 100 μM of selected commercially 
readily available pregnane X receptor  ligands (Goodwin et al., 1999; Honkakoski et al., 
2003) with the OATP1B1- and 1B3-expressing CHO cells. The results are summarized 
in Fig. 2. Rifampicin, a known substrate of OATP1B1 and of 1B3 (Vavricka et al., 2002) 
was used as a positive control and inhibited almost complete uptake mediated by both 
OATPs. Phenytoin had almost no effect, whereas all other pregnane X receptor ligands 
inhibited OATP1B1-mediated transport in a concentration dependent way. Paclitaxel has 
been shown to be a substrate for OATP1B3 but not for 1B1 (Smith et al., 2005). 
Nevertheless, it inhibited OATP1B1-mediated uptake stronger than uptake mediated by 
OATP1B3. In addition to paclitaxel, mifepristone, mevinolin, troglitazone, lithocholate 
and estradiol were strong inhibitors of OATP1B1-mediated estradiol-17β-glucuronide 
uptake (Fig. 2). Inhibition of OATP1B3-mediated estradiol-17β-glucuronide was less 
pronounced, but again paclitaxel, mifepristone, mevinolin and troglitazone were the 
strongest inhibitors. Interestingly, clotrimazole, which inhibited OATP1B1-mediated 
uptake, stimulated OATP1B3-mediated uptake at both concentrations (Fig. 2).  
To estimate whether these pregnane X receptor ligands could inhibit uptake under 
normal pharmacological conditions, we determined the IC50 values for the compounds 
where free plasma concentrations are available.  In Table 2 these results are 
summarized and compared to the respective free plasma concentrations. Based on the 
obtained IC50 values, rifampicin, paclitaxel, mifepristone and troglitazone are effective 
inhibitors of OATP1B1-mediated transport at concentrations that are reached in blood 
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plasma. For OATP1B3 only rifampicin and mifepristone have IC50 values that would 
suggest potential interactions at the free plasma concentrations. We also examined the 
correlation between the IC50 values and the respective affinities to pregnane X receptor 
(Table 2) but we did not obtain any significant correlation, suggesting that the residues 
lining the transport/binding sites on OATP1B1 and 1B3 are quite different from those of 
the binding site(s) on pregnane X receptor.    
 
3.3 Effect of clotrimazole and other azoles on substrate uptake 
Because clotrimazole had such a different effect on OATP1B1 and 1B3 mediated 
transport of estradiol-17β-glucuronide, we further characterized this inhibition/stimulation 
and performed kinetic experiments. Fig. 3 shows that clotrimazole inhibited OATP1B1-
mediated estradiol-17β-glucuronide uptake in a competitive way, affecting the apparent 
affinity but not the maximal transport rates. We calculated a Ki value of 7.7 ± 0.3 μM 
from three independent experiments. Stimulation of OATP1B3-mediated estradiol-17β-
glucuronide uptake by clotrimazole was due to increased apparent affinity. At 10 μM 
clotrimazole, the apparent Km value decreased from 9.5 to 8.7 μM and at 100 μM 
clotrimazole to 4.7 μM without affecting the maximal transport rates. However, when we 
tested whether [3H]clotrimazole is a transported substrate for OATP1B1 and/or 1B3, we 
did not find any uptake up to 10 μM clotrimazole, although the cells transported the 
positive control estradiol-17β-glucuronide. 
We next compared OATP-mediated uptake of estradiol-17β-glucuronide, estrone-3-
sulfate and Fluo-3 in the presence of increasing concentrations of clotrimazole. As 
shown in Fig. 4, clotrimazole inhibited OATP1B1-mediated uptake independent of the 
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transported substrate in a concentration dependent manner. However, the effect of 
clotrimazole on OATP1B3-mediated uptake was dependent on the transported 
substrate. Consistent with the results shown in Fig. 3, clotrimazole stimulated estradiol-
17β-glucuronide uptake at all concentrations tested with a maximal effect at 50 μM. 
Estrone-3-sulfate uptake was minimally affected, whereas Fluo-3 transport was inhibited 
in a concentration dependent way. Six additional OATP substrates were tested in the 
absence and presence of 50 μM clotrimazole. As can be seen from the results 
summarized in Table 3, clotrimazole clearly stimulated OATP1B3-mediated estradiol-
17β-glucuronide uptake. Uptake of estrone-3-sulfate was slightly higher in the presence 
of clotrimazole while transport of all other substrates was inhibited.  
In order to examine whether additional azole derivatives would exert a similar effect on 
OATP-mediated estradiol-17β-glucuronide uptake, we measured transport in the 
presence of miconazole, ketoconazole and fluconazole at 10 and 100 μM. OATP1B1-
mediated uptake was inhibited by all three compounds, whereas OATP1B3-mediated 
uptake was only inhibited by ketoconazole (Fig. 5).  
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4. Discussion 
The experiments presented here show that several pregnane X receptor ligands interact 
with uptake mediated by human OATP1B1 and 1B3 at pharmacological concentrations. 
Therefore, these pregnane X receptor ligands have the potential to cause adverse 
interactions with other drugs that are transported by the two liver specific OATPs. In 
agreement with previously reported studies for several drugs (Campbell et al., 2004; 
Hirano et al., 2006; Shitara et al., 2003; Vavricka et al., 2002) most tested pregnane X 
receptor  ligands inhibit OATP1B1- and OATP1B3-mediated uptake. Clotrimazole is a 
common drug that is applied locally in the treatment of vaginitis and can reach estimated 
plasma concentrations similar to the concentrations used in our experiments (Ritter et 
al., 1982). At these concentrations clotrimazole inhibited OATP1B1 but stimulated 
OATP1B3, and thus can possibly alter the pharmacokinetic properties of drugs cleared 
by these two transporters in opposite ways. While inhibition of OATP1B1 could 
potentially lead to increased drug plasma levels, stimulation of OATP1B3 could lead to 
enhanced drug removal and thus to lower plasma concentrations.  
Clotrimazole increased the affinity of OATP1B3 for estradiol-17β-glucuronide, probably 
through a conformational change of the protein, which does not seem to be allosteric. 
We are currently constructing chimeras and performing site-directed mutagenesis to 
further explain the exact molecular mechanism of this activation of substrate transport. 
Such stimulation could be a general mechanism to stimulate OATP-mediated uptake. 
This is supported by the stimulation of Oatp1a4-mediated taurocholate transport by 
estradiol-17β-glucuronide (Sugiyama et al., 2002), as well as the recent finding that 
progesterone can stimulate OATP2B1-mediated transport (Grube et al., 2006). All these 
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effects seem to be substrate dependent. While estradiol-17β-glucuronide uptake 
mediated by OATP1B3 was strongly stimulated by clotrimazole we could not reproduce 
the stimulation of taurocholate transport by estradiol-17β-glucuronide that was reported 
for rat Oatp1a4 (Sugiyama et al., 2002) with either OATP1B1 or 1B3 (data not shown). 
Nevertheless, this finding supports the hypothesis that substrates, as in the case of 
OCT1 (Gorboulev et al., 2005), interact with OATP1B3 at different binding sites.  
These comparable findings for several OATPs (OATP1B3, this study; Oatp1a4 
(Sugiyama et al., 2002); OATP2B1 (Grube et al., 2006)) suggest that this could be a 
common phenomenon among all multispecific OATPs, explaining at least in part the 
molecular basis for the multispecificity. Additional evidence for multiple binding sites 
comes from the inhibition experiments shown in Fig. 2. OATP1B1 mediated estradiol-
17β-glucuronide uptake can be inhibited completely with 100 μM rifampicin. 
Nevertheless, both, 10 and 100 μM lithocholate inhibited this uptake only by about 70%, 
suggesting different estradiol-17β-glucuronide transport/binding sites that are not 
completely inhibited by lithocholate.  
Besides clotrimazole, we also tested the effect of additional azole derivatives 
(miconazole, ketoconazole and fluconazole) on OATP1B1- and OATP1B3-mediated 
uptake. None of these compounds stimulated OATP1B3-mediated uptake, suggesting 
that it is not the azole structure that is responsible for the stimulation effect of 
clotrimazole. However, additional experiments are needed to identify the molecular 
components of these azole derivatives that are responsible for inhibition or stimulation 
by interacting with OATPs. 
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Our results further demonstrate that the OATP1B1- and OATP1B3-expressing CHO 
cells described in this study are useful tools to screen for interactions between the 
expressed OATPs and pregnane X receptor ligands or other potential interacting 
compounds. These cell lines exhibit the highest Vmax values published so far. The Km 
values for estradiol-17β-glucuronide uptake are comparable to previously published data 
for both, OATP1B1- and OATP1B3-mediated transport (Hirano et al., 2004; König et al., 
2006; Nakai et al., 2001). Similarly, the values for OATP1B1-mediated estrone-3-sulfate 
transport agree well with previously published values (Hirano et al., 2004; König et al., 
2006; Nozawa et al., 2002). However, so far no Km values have been published for 
estrone-3-sulfate transport mediated by OATP1B3. Two groups reported that there was 
no detectable estrone-3-sulfate transport in their HEK293 cells expressing OATP1B3 
(Cui et al., 2001b; Hirano et al., 2004), whereas two other reports documented estrone-
3-sulfate transport in OATP1B3 expressing MDCKII and HEK293 cells (Letschert et al., 
2004) and in Xenopus laevis oocytes (Kullak-Ublick et al., 2001). This discrepancy can 
be explained by lower expression levels (several fold lower Vmax values) obtained in 
HEK293 cells compared to the expression levels in the CHO cells used in our studies. 
With respect to Fluo-3, two previous reports showed that this calcium indicator is a 
substrate of OATP1B3 (Baldes et al., 2006; Cui et al., 2001a). Our studies extend those 
findings and show that Fluo-3 is also a substrate of OATP1B1, only with a much lower 
transport capacity. 
Among the tested pregnane X receptor ligands, paclitaxel exhibited the strongest 
inhibition for both, OATP1B1- and OATP1B3-mediated uptake. A recent study 
demonstrated that paclitaxel is transported by OATP1B3-expressing Xenopus laevis 
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oocytes, but not by OATP1B1-expressing oocytes (Smith et al., 2005). Preliminary 
results obtained with our cell lines indicate that paclitaxel is indeed transported by both 
OATP1B1 and 1B3, although with different affinities (data not shown). Further 
experiments are required to elaborate these results and determine the affinity constants.  
In summary, we have demonstrated that many pregnane X receptor ligands interact with 
OATP1B1- and 1B3-mediated substrate uptake. Clotrimazole which is not a transported 
substrate is able to stimulate OATP1B3-mediated uptake of certain compounds. 
Therefore, co-administration of drugs with compounds that interact with OATP-mediated 
transport has the potential to increase or decrease the bioavailability of these drugs and 
result in adverse drug-drug interactions. In addition, our OATP1B1- and 1B3-expressing 
CHO cells are excellent tools for the investigation of the multispecificity of these two 
important transporters. Furthermore, the presented results suggest that a detailed 
understanding of the molecular mechanisms of OATP-mediated transport will help to 
avoid adverse drug-drug interactions at the transporter level in the process of drug 
development. 
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Figure Legends 
 
Fig. 1. Immunohistochemical (A, B) and functional (C, D) characterization of OATP1B1- 
and 1B3 expressing CHO cell lines. CHO cells expressing either OATP1B1 (A) or 
OATP1B3 (B) were grown on culture slides and stained with an anti-OATP1B1 or anti-
OATP1B3 antibody (red color) while nulcei were visualized with DAPI (see Materials and 
Methods). Uptake of increasing concentrations of [3H]estradiol-17β-glucuronide was 
measured at 37 °C for 20 s with OATP-expressing and wild-type CHO cells. After 
subtracting the values obtained with wild-type cells, net OATP1B1 (C) and OATP1B3 
(D) mediated uptake was fitted to the Michaelis-Menten equation to obtain Km and Vmax 
values. Means ± S.D. of triplicate determinations are given. 
 
Fig. 2. Effect of pregnane X receptor ligands on OATP-mediated estradiol-17β-
glucuronide uptake in stable transfected CHO cells. Uptake of 1 μM [3H]estradiol-17β-
glucuronide was measured at 37 °C for 20 s with OATP-expressing and wild-type CHO 
cells in the absence or presence of the indicated pregnane X receptor ligands. Values 
obtained with wild-type CHO cells were subtracted from values obtained with OATP-
expressing CHO cells and are given as percent of the control. Means ± S.D. of triplicate 
determinations are given; * P < 0.05. 
 
Fig. 3. Kinetic analysis of estradiol-17β-glucuronide transport by OATP1B1 and 
OATP1B3 in the absence and presence of clotrimazole. Uptake of increasing 
concentrations of [3H]estradiol-17β-glucuronide was measured at 37 °C for 20 s with 
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OATP-expressing and wild-type CHO cells in the absence or presence of clotrimazole. 
After subtracting the values obtained with wild-type cells, net OATP-mediated uptake 
was fitted to the Michaelis-Menten equation to obtain Km and Vmax values. Means ± S.D. 
of triplicate determinations are given. Clotrimazole concentrations in the case of 
OATP1B1 were 10 (open circles) and 30 μM (closed triangles) and in the case of 
OATP1B3 10 (open circles) and 100 μM (closed triangles). The inset shows a Dixon plot 
for the inhibition kinetics of OATP1B1-mediated transport. 
 
Fig. 4. Effect of clotrimazole on OATP-mediated substrate uptake. Uptake of the 
indicated substrates was measured at 37 °C with OATP-expressing and wild-type CHO 
cells in the absence and presence of increasing concentrations of clotrimazole. Values 
obtained with wild-type CHO cells were subtracted from values obtained with OATP-
expressing CHO cells and are given as percent of the control. Means ± S.D. of triplicate 
determinations are given. 
 
Fig. 5. Effect of azole derivatives on OATP-mediated estradiol-17β-glucuronide 
transport. Uptake of 1 μM [3H]estradiol-17β-glucuronide was measured at 37 °C for 20 s 
with OATP-expressing and wild-type CHO cells in the absence or presence of the 
indicated azole derivatives. Values obtained with wild-type CHO cells were subtracted 
from values obtained with OATP-expressing CHO cells and are given as percent of the 
control. Means ± S.D. of triplicate determinations are given; * P< 0.05. 
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Table 1 
Kinetic parameters of OATP1B1- and OATP1B3-expressing CHO cells 







5.4 ± 2.5 360 ± 46 66.7 
 Estrone-3-sulfate 2.4 ± 0.8 340 ± 40 142 
 Fluo-3 2.3 ± 0.2 78 ± 211) 0.034 
OATP1B3 Estradiol-17β-
glucuronide 
15.8 ± 2.5 360 ± 28 22.8 
 Estrone-3-sulfate 58 ± 20 1860 ± 325 32 
 Fluo-3 3.1 ± 0.4 630 ± 1001) 0.203 
 
1) fmol/mg/min 
Initial transport rates (20 s for estradiol-17β-glucuronide and estrone-3-sulfate; 10 min 
for Fluo-3) at increasing concentrations were determined at 37 °C in OATP-expressing 
and wild-type CHO cells. Transport values were corrected with values obtained from 
wild-type cells and the resulting net carrier mediated uptake values were fitted by 
nonlinear regression analysis to the Michaelis-Menten equation. Mean ± S.E. are given 
for 2-7 experiments. 
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Table 2 
Comparison of IC50 values of pregnane X receptor ligands for inhibition of OATP1B1 and 
1B3 mediated estradiol-17β-glucuronide uptake with unbound plasma concentrations 



















Rifampicin 1.5 2.6 0.7-2.4 (Brunton et 
al., 2005)  
0.71 (Moore et al., 
2000) 
Paclitaxel 0.03 0.5 0.085 (Brunton et al., 
2005) 
5 (Synold et al., 
2001) 
Mifepristone 3.3 5.3 1.9 (Sarkar, 2005) 5.5 (Moore et al., 
2000) 
Mevinolin 6.1 92.6 0.006 (Brunton et al., 
2005) 
1-5 (Lehmann et 
al., 1998) 
Clotrimazole 9.0  2 (Tiffert et al., 2000) 1.6 (Moore et al., 
2000) 
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Carbamazepine 188 510 9.7 (Brunton et al., 
2005) 
N.A. 
Troglitazone 1.2 15.7 1-3 (Asano et al., 
1999) 
3 (Jones et al., 
2000) 
Lithocholate 0.7 6.8 0.05 (Castano et al., 
2006) 
9 (Staudinger et 
al., 2001) 




IC50 values were calculated using non-linear regression analysis and SigmaPlot; N.A.: 
not available 
  Page 29 
Table 3 
Effect of clotrimazole on OATP1B1- and OATP1B3-mediated substrate uptake 
OATP1B1 Uptake (fmol/mg) OATP1B3 Uptake (fmol/mg) 
Substrate Clotrimazole (50 µM) 
-                         + 
Clotrimazole (50 µM) 
-                        + 
Estradiol-17β-
glucuronide 
141.2 ± 15.0 39.1 ± 3.2 40.7 ± 6.1 103.5 ± 8.3 
Estrone-3-sulfate 760.9 ± 30.3 365.5 ± 8.9 43.9 ± 3.7 51.1 ± 2.6 
CCK-8 5.9 ± 0.4 1.0 ± 0.9 80.1 ± 4.2 64.9 ± 1.8 
DPDPE 3.2 ± 1.7 1.0 ± 0.6 21.8 ± 2.2 11.0 ± 1.5 
Etoposide 216.0 ± 50.4 74.7 ± 59.4 452.6 ± 55.8 257.5 ± 61.2 
Paclitaxel 166.5 ± 22.9 16.6 ± 7.3 173.8 ± 24.2 16.4 ± 13.2 
Taurocholate 5.2 ± 1.5 1.4 ± 1.5 30.1 ± 4.1 16.5 ± 1.8 
Thyroxine 3.6 ± 1.4 1.0 ± 0.6 3.3 ± 1.0 0.2 ± 0.4 
 
Uptake of tracer compounds was determined under initial linear rates (20 s) in the 











































































Km = 5.4 ± 2.5 μM
C
Vmax = 360 ± 46 pmol/mg/min
Km = 15.8 ± 2.5 μM
D
Vmax = 360 ± 28 pmol/mg/min
Figure 1
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